Advaxis (ADXS) Issues Earnings Results

Advaxis (NASDAQ:ADXS) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.14), Fidelity Earnings reports. Advaxis had a negative net margin of 1,062.68% and a negative return on equity of 165.23%.

Advaxis stock traded down $0.03 during mid-day trading on Friday, reaching $0.32. The stock had a trading volume of 111,758 shares, compared to its average volume of 1,353,548. The stock has a market cap of $18.86 million, a price-to-earnings ratio of -0.14 and a beta of 2.92. Advaxis has a one year low of $0.18 and a one year high of $3.30.

ADXS has been the topic of a number of recent research reports. ValuEngine raised shares of Advaxis from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. HC Wainwright set a $2.00 target price on shares of Advaxis and gave the stock a “buy” rating in a research report on Tuesday, November 6th.

WARNING: “Advaxis (ADXS) Issues Earnings Results” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at

About Advaxis

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Read More: How Do Front-End Loads Impact an Investment?

Earnings History for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with's FREE daily email newsletter.

Leave a Reply